Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications

"Ask Extractor” and “Journal Trends” Help Researchers Narrow Search Results 

Amsterdam, 16 June, 2011 – Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced two new applications from Molecular Connections, a life science informatics company, on SciVerse Applications beta.

Ask Extractor is an application based on Molecular Connections XTractor, a platform for discovery, analysis and modelling of biomedical information. The application provides search suggestions for life sciences terms entered into SciVerse Hub and SciVerse ScienceDirect. The second application, Journal Trends, enables users to discover top journals as a result of a given search query.

“Due to the enormous amount of published scientific information, applications that refine and simplify search results, or assist in creating a targeted query, can significantly benefit researcher workflows,” said Vidyendra Sadanand, Chief Technology Officer of Molecular Connections.

“Molecular Connections has significant expertise in providing solutions to the life science research community,” said Rafael Sidi, Vice President, Application Marketplace and Developer Network at Elsevier. “We look forward to continuing our work with Molecular Connections and the developer community to deliver applications that will improve researchers’ productivity.”

SciVerse Applications and the Developer Network provide opportunities for researchers and librarians to collaborate with developers in creating and promoting new applications that improve research workflows. The Developer Network features a growing community of application developers that gain potential recognition, prestige and revenue through their contributions to SciVerse Applications.

# # #

About Molecular Connections
Molecular Connections (www.molecularconnections.com) is a pioneering In silico Discovery Services Company. It provides high quality, cost effective curation, literature informatics solutions and annotation services as well as products. Customers of Molecular Connections include leading pharmaceutical and biotechnology, drug discovery, genomics, proteomics, medical technology, equipment companies and academic institutions spanning across the globe. In addition, Molecular Connections has powerful tool development, database integration, effective data visualization capabilities, specific expertise in building knowledge bases for rapidly growing needs in, ADME Tox, clinical, drugs, chemistry and patent industries. For more information write to Krishna Chinnaia at krishna@molecularconnections.com.

About the Elsevier SciVerse Suite
The SciVerse (www.sciverse.com) suite of search and discovery offerings provides the global research community access to a constantly expanding universe of content and solutions which can now be accessed in one platform. The suite currently includes SciVerse ScienceDirect (www.sciencedirect.com), the world’s largest source of peer-reviewed content containing more than 10 million articles, and SciVerse Scopus (www.scopus.com), an abstract and citation database containing 41 million records, 70% with abstracts and nearly 18,000 titles from 5,000 publishers worldwide. The platform also includes SciVerse Hub beta (www.hub.sciverse.com), which enables researchers to perform a single search across all of the SciVerse content as well as targeted web content with results ranked by relevancy and without duplication. SciVerse Applications (www.applications.sciverse.com) and Developer Network (www.developers.sciverse.com) allow the scientific community to build, find and use applications that enhance the SciVerse research experience.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Sandra Plasse
splasse@psbpr.com
+1 212 752 8338